A bipartisan group of 37 members of the House of Representatives have co-sponsored the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, H.R. 3742, which has been promoted by IDSA. The ADAPT Act would permit a new antibiotic’s safety and effectiveness to be studied in smaller, more rapid clinical trials. In return, the drug would be narrowly indicated for use in a limited population of patients. ADAPT includes provisions to help guide the appropriate use of these drugs including: requiring the label to state the drug’s limited indication, granting the Food and Drug Administration authority to pre-review the drug’s promotional materials, and directing the Centers for Disease Control and Prevention (CDC) to monitor the drug’s use. IDSA is also advocating for the inclusion of a visual element on the drug’s label to clearly mark the drug as different from traditional antibiotics.
IDSA is urging additional members of the House to cosponsor the legislation so that it might be advanced this fall. IDSA members can support this effort in just a few minutes by emailing their representative through the IDSA Action Center today.
< Previous Article | Next Article >